LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday it has continued to perform well, with revenue up "strongly" from the prior year and sales in line with market expectations.
Allergy Therapeutics' financial year runs to June 30. In the recent year, the company recorded a GBP6.9 million loss on revenue of GBP68.3 million.
Furthermore, the biotechnology company said it continued to gain market share especially in Germany.
"Our revenue growth reflects the quality of our products, the strength of our supply chain and our sales and marketing team. We are pleased that we have continued to make headway this year both in market share and in the progress of our pipeline," Chief Executive Officer Manuel Llobet said.
Allergy Therapeutics shares were trading down 0.3% at 15.71 pence each on Tuesday afternoon.